On September 30, 2023, NEUROPACE ($NASDAQ:NPCE) announced its Q3 FY2023 earnings results with total revenue for the quarter amounting to USD 16.4 million, a 47.2% increase compared to the same quarter of the previous year. Net income for Q3 of FY2023 was USD -7.3 million, a decrease from the net income of -11.8 million registered in the same quarter of the prior year.
On Monday, NEUROPACE reported record earnings for the third quarter of the fiscal year 2023. The company’s stock opened at $7.0 and closed at $7.2, up by 0.4% from last closing price of $7.2. The company attributes its success to its relentless focus on innovation and developing cutting-edge technologies. NEUROPACE has made significant investments in research and development to stay ahead of the curve in an ever-changing market. It claims to have developed several products that are highly efficient and cost-effective, helping to drive down the overall cost of medical care. The company has also worked to establish strategic partnerships with key medical providers to increase its market reach and spread its innovative technologies.
In addition, the company has also strengthened its international presence by expanding into new markets in Europe, Asia, and Latin America. Overall, NEUROPACE is confident that it can continue to build on the success of its Q3 performance and deliver value to its shareholders. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Neuropace. NEUROPACE_Reports_Record_Q3_Earnings_for_FY2023″>More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Neuropace. NEUROPACE_Reports_Record_Q3_Earnings_for_FY2023″>More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Neuropace. NEUROPACE_Reports_Record_Q3_Earnings_for_FY2023″>More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Neuropace are shown below. NEUROPACE_Reports_Record_Q3_Earnings_for_FY2023″>More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Neuropace Intrinsic Stock Value
GoodWhale has conducted an extensive financial analysis of NEUROPACE to provide an accurate valutation of their stock. Our proprietary Valuation Line has revealed the fair value of their shares to be around $10.8. As such, this may provide an opportunity for investors to acquire a bargain. More…
Star Chart Analysis
The competition between NeuroPace Inc and its competitors is fierce. Each company is vying for a share of the market, and each has its own strengths and weaknesses. NeuroPace Inc has a strong product, but its competitors are not far behind. Aziyo Biologics Inc has a good product, but it is not as well known as NeuroPace Inc. Dignitana AB has a good product, but it is not as widely available as NeuroPace Inc. Guided Therapeutics Inc has a good product, but it is not as well known as NeuroPace Inc.
Aziyo Biologics Inc is a medical technology company that focuses on the development and commercialization of products for the regeneration and repair of human tissue. The company has a market capitalization of 109.11 million as of 2022 and a return on equity of -718.74%. The company’s products are used in a variety of applications, including wound care, orthopedics, and cardiovascular surgery.
Dignitana AB is a Swedish company that designs and manufactures scalp cooling systems to prevent hair loss during chemotherapy. The company’s products are FDA-cleared and CE-marked, and are used by cancer patients in over 30 countries. Dignitana AB’s products are available through a network of distributors and partners worldwide.
– Guided Therapeutics Inc ($OTCPK:GTHP)
Guided Therapeutics Inc is a medical device company that develops, manufactures, and markets Molecularly Guided Surgery products to detect and treat cancer. The Company’s products include the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical cancer; and the LuViva Selective Laser Ablation System, a minimally invasive device used to treat cervical cancer. Guided Therapeutics Inc is headquartered in Atlanta, Georgia.
Analysts are largely positive about NEUROPACE following their Q3 FY2023 earnings results, as total revenue for the quarter saw a 47.2% year-over-year increase to USD 16.4 million. Despite this, net income was reported at a loss of -7.3 million, down from -11.8 million in the previous year. Going forward, investors should be cautiously optimistic as the company looks to capitalize on its strong revenue growth and improve its profitability.